Date / Time : July 23 13:30-16:30

Venue : Taipei Nangang Exhibition Center, Hall 2 (Room 701E)
Co-organizer : 台灣生物產業發展協會、資誠聯合會計師事務所(PwC)

Time	Topic	Speaker
13:30-13:50	開幕致詞及貴賓合影	Eric Crowley 代理組長 美國在台協會商務組
13:50-14:10	健康台灣癌症政策治療願景與現況分析	主持人 Nick Meadows 總監 PwC資誠澳洲 林冠宏 主持會計師 PwC資誠創新與AI智慧醫材產業
14:10-14:35	由臨床數據收集支持新藥治療評估與給付決策	梁賡義 董事長 台灣生醫大數據科技股份有限公司
14:35-15:00	從接軌指引到降低死亡率，體現少見癌症治療政策願景	魏裕峯 部長 義大癌治療醫院內科部
15:00-15:20	茶敘
15:20-16:10	焦點座談 ▪ 邁向降低死亡率，如何提升難治型癌症治療效益   ▪ 癌症新藥基金元年，以數位科技導入真實世界數據評估健保藥物收載   ▪ 健康台灣啟航，促進醫療永續投資	主持人 郭志峰 博士 台灣區電機電子工業同業公會 智慧醫療健康科技委員會 產業政策組召集人 與談人 石崇良 署長 衛生福利部中央健康保險署 沈延盛 院長 國立成功大學醫學院 魏裕峯 部長 義大癌治療醫院內科部 梁賡義 董事長 台生科股份有限公司 My Linh Kha Sr. VP&GM JAPAC Amgen 劉桓睿 秘書長 台灣年輕病友協會
16:10-16: 30	現場提問	與會貴賓
16:30-	閉幕

Session Synopsis:
國民健康不僅是國家發展的體現，更是建立具韌性與包容性社會的根基。為實踐此一願景，於民國113年6月正式宣布於總統府成立「健康台灣推動委員會」，作為跨部門對話與國家健康政策推動的平台，期望凝聚全民共識並推動實際行動。
在此政策架構下，政府陸續啟動癌症篩檢擴大、精準健康推動以及「癌症新藥基金」等重點措施，積極回應健康平權、醫療創新與永續照護的國家發展需求。本次論壇邀集健保署決策代表、臨床專家及真實世界證據學者，針對臨床價值與給付、資料治理、政策現況與優化等癌症照護政策關鍵議題進行討論。
期望透過跨領域的交流，形成具共識、可執行的政策建議，共同推進癌症新藥治理架構的制度創新，實現健康台灣的共同願景。

Date / Time :July 24 14:00-17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 402C)
Co-organizer: LumiSTAR Biotechnology, Molecular Devices

Time	Topic	Speaker
14:00-14:10	Opening Remarks	Woolen Pan General Manager, Taiwan/Hong Kong/Macau, Molecular Devices (HK)
14:10-14:40	Modernizing Drug Discovery: Innovative Human iPSC-Derived 3D Models as Animal Testing Alternatives	Yu-Fen Chang CEO and founder, LumiSTAR Biotechnology
14:40-15:10	Leveraging High-Throughput Screening in Biomedical Research: From Principles to Practice	Ting-Jen Cheng Senior Research Specialist/Scientist, Genomics Research Center, Academia Sinica
15:10-15:35	Shifting Paradigms Together: Making Human-Relevant Model-Based Research More Accessible	Bella Tsai Product Manager, Molecular Devices (HK)
15:35-15:50	Tea Break & Networking & Group Photo
15:50-16:20	Building Better Brain Drugs: Key Considerations in Early CNS Drug Discovery	Elsa Liu Technical Director, Eurofins Panlabs Discovery Services Taiwan
16:20-16:50	Designing Microenvironments and Nanosurfaces for Controlling iPSCs and Their Application in Drug Screening and Regenerative Medicine	Li Liu Professor, Osaka University; CTO and founder, EngiTissue Design
16:50-17:00	Closing Remarks	Yu-Fen Chang  CEO and founder, LumiSTAR Biotechnology

Session Synopsis:
Join us for an illuminating symposium exploring the forefront of drug discovery innovation. This session brings together leading experts to showcase how cutting-edge human iPSC-derived 3D models, engineered microenvironments, and high-throughput screening technologies are transforming the landscape of biomedical research and therapeutic development.
Discover how advances in stem cell biology are enabling animal-free drug testing, in line with the FDA Modernization Act 3.0. Learn about the latest breakthroughs in designing nanosurfaces and microenvironments for precise control of iPSCs, and their applications in both drug screening and regenerative medicine. Gain insights into the unique challenges and opportunities in early CNS drug discovery, and see how high-throughput screening is accelerating research from principle to practice.
Whether you are a scientist, product manager, or industry leader, this session will provide actionable knowledge and a holistic perspective on the next generation of drug discovery tools and strategies.

 

Date / Time : July 24 08:00-17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 403)

Co-organizer : Taiwan Bio Therapeutics INC.

Time	Topic	Speaker
08:00-08:30	Registration
08:30-09:00	Opening Remarks	Session Chair: Cyrus Yang
09:00-10:00	Discovery of New Immunotherapy Targets and Mechanisms Leveraging CRISPR	Arlene H. Sharpe Kolokotrones University Professor｜Harvard Medical School
10:00-10:30	Coffee Break
10:30-11:30	Tfr Regulation of Antibody Mediated Diseases	Peter T. Sage Associate Professor of Medicine｜Harvard Medical School and Brigham and Women's Hospital
11:30-13:00	Lunch Break
13:00-14:00	Therapy in Autoimmunity with a Focus on Inflammatory Bowel Disease	William A. Faubion Dean of Research, MCA｜Mayo Clinic  Executive Medical Director, CRB｜Mayo Clinic
14:00-15:00	Polymeric Particles for Immunomodulation	Jordan J. Green Herschel L. Seder Professor of Biomedical Engineering｜Johns Hopkins University School of Medicine
15:00-15:20	Coffee Break
15:20-16:20	Industry Perspective: Polyclonal Regulatory T Cell Therapy  in Solid Organ Transplantation Clinical Trials	Cyrus Yang CEO｜Taiwan Bio Therapeutics INC.
16:20-17:00	Panel Discussion & Concluding Remarks	Moderator: Cyrus Yang Panelists: Arlene H. Sharpe, Peter T. Sage, William A. Faubion, Jordan J. Green

Session Synopsis:
Regulatory T cells (Tregs) have long been recognized as central mediators of immune tolerance. What distinguishes the current moment in the field is the maturity of science and technology, which now makes it possible to translate decades of discovery into real therapeutic opportunities. With growing momentum in clinical trials and the advent of genetic engineering to enhance Treg stability, specificity, and function, Treg-based therapies are rapidly evolving from concept to clinic—offering new hope for patients with autoimmune diseases and for preventing transplant rejection.
Treg Symposium 2025 offers a timely and focused platform to explore these advances. By bringing together leading experts from both academia and industry, the symposium fosters the kind of interdisciplinary dialogue essential for addressing the scientific, clinical, and manufacturing challenges of Treg therapy. Topics will span from cutting-edge tools for understanding Treg biology and discovering new therapeutic opportunities, to clinical-stage developments of ex vivo Treg therapies and emerging strategies for in vivo Treg modulation.

Date / Time : July 24 13:00–17:30

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 503)

Co-organizer : Promega Corporation

Time	Topic	Speaker
13:00-13:30	Registration
13:30	Opening	LayPing Lee Director, Sales & Marketing Promega Corporation, Singapore
13:35-14:20	Illuminating Biologics Drug Discovery with Innovative Assays	Dr. Frank Fan Head of Biology, R&D Promega Corporation, U.S.A
14:20-15:20	The Bioluminescent Toolbox for Vaccine Characterization and mRNA Quality Control	Dr. Jamison Grailer Senior Research Scientist Promega Corporation, U.S.A
15:20-15:50	Promega Bioassays: Enabling Reliable Methodology for Research and Industrial Advancement	Dr. Mei-Wei Lin Manager Industrial Technology Research Institute
15:50-16:00	Break
16:00-16:30	Bioassays Development for Product Release and Characterization - From a CDMO Perspective	Dr. Toby Hong Associate Director of Analytical/Formulation Development & Cell Line/Cell Culture Process Development Bora Biologics
16:30-17:20	Bioluminescent Platform Technologies for Functional Characterization of Advanced Cancer Therapeutics	Dr. Jamison Grailer Senior Research Scientist Promega Corporation, U.S.A
17:20	Closing	Dr. Frank Fan Head of Biology, R&D Promega Corporation, U.S.A

Date / Time : July 24 15:30-17:30

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 504A)
Co-organizer: 經濟部產業技術司、資策會科技法律研究所、台灣生物產業發展協會

Time	Topic	Speaker
15:30-16:00	來賓報到
16:00-16:10	開場致詞	林冠宇 主任 資策會科法所 跨域整合中心
16:10-16:40	創新藥品加速上市法制研析	張慧潔 法律研究員 資策會科法所 跨域整合中心
16:40-17:10	國際藥廠新藥加速上市策略	寇怡衡 主任 生物技術開發中心 企劃管考室
17:10-17:30	QA & Networking

 

Date / Time : July 25 09:30-12:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 402AB)
Organizer: 訊聯細胞智藥股份有限公司
Co-organizer: 清冠一號團隊、寶泰生醫、羅麗芬集團、iShine愛閃耀、AKIMIA、翰醫堂、大添生醫、博而美國際

Time	Topic
09:30-10:00	來賓報到
10:00-10:10	貴賓致詞
10:10-10:30	【Exosome Foundry．大勢成形】驅動外泌體再生醫學產業新未來
10:30-10:55	【Exosome Foundry x AI智慧研發】創新佈局及應用 ■ 清冠一號團隊－以醫領藥．以藥帶農： 全新功能性中草藥外泌體「清泌一號」翻轉台灣中草藥產業生態鏈 ■寶泰生醫－寵物市場新商機： 寵物幹細胞結合外泌體，為毛小孩量身打造寵物再生醫學時代 ■羅麗芬集團－40年肌膚管理再升級： 台灣特有植萃結合訊聯哺乳類幹細胞外泌體，經北醫大皮膚科臨床驗證，創造科研級修護新標準，全球五千店同步見證 ■ iShine愛閃耀－外泌體x PRP雙效科技： 美妝保養導入AI，由內而外啟動女性保養新風潮，開創業界標竿 ■ AKIMIA－微電流美容新應用： AI外泌體結合獨步全球微電流面膜，打造新時代居家美容革新修護力 ■ 翰醫堂－中醫漢方進軍國際： 翰方植萃外泌體導入中醫特色醫療服務，助力跨境海外華人市場 ■大添生醫－創新農業價值：  AI發掘薑黃外泌體潛力，從有機農業跨足再生醫學，邁向高值國際市場 ■ 博而美國際－醫材應用再進化：  40年醫材代理大廠憑藉無限電波、麗珠蘭聲勢，更導入外泌體前瞻科技，助攻醫療領域全新應用
10:55-12:00	交流時間

Session Synopsis:
感謝您對訊聯集團活動的關注，我們正誠徵全球代理合作！

「Exosome Foundry外泌體全球研發代工」服務模式於2024年推出後，服務涵蓋超過20+業態、16大醫學領域，訊聯集團結合獨家AI製程技術，篩選出有效miRNA生產功能性外泌體，將客製化產品做出市場區隔，幫助客戶跨領域產業再生醫學化。

我們將於7月25日於亞洲生技大展中舉辦年度「Exosome Foundry Demo Day」，透過訊聯，您也能輕鬆進入再生醫學領域，共享兆元產業商機

若您有外泌體相關服務需求或合作興趣，歡迎留下您的聯繫方式，謝謝！

Date / Time : July 25 14:00-17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 402AB)
Co-organizer: 訊聯基因數位股份有限公司、社團法人台灣生物產業發展協會

Time	Topic	Speaker
14:00-14:20	來賓報到
14:20-14:35	貴賓致詞
14:35-15:20	AI 賦能藥物研發：新藥開發創新路徑	蔡耿彰 教授 衛生福利部國家中醫藥研究所 Lucas Nivon CEO, Cyrus Biotechnology 白宗彬 資深研究員 安基生技新藥股份有限公司
15:20-15:50	AI賦能藥品研發與實驗室自動化：加速藥品品質管理與生產製程革新	華鵬 BIOVIA生命科學解決方案顧問, Dassault Systèmes 張佐維 董事長 萊斯特生醫股份有限公司
15:50-15:55	Q&A
15:55-16:10	AI智慧製藥實踐轉型路徑：電子批次紀錄引領製藥製程與品質變革	Jack Lim Regional Account Executive, Asia Pacific, MasterControl
16:10-16:15	Q&A
16:15-17:00	AI Platform Demonstration

Session Synopsis:
在全球AI時代的到來，AI技術正加速驅動從藥物設計、品質控管到製造生產的整體革新。本論壇以「AI賦能 智藥時代：藥物設計 × 品質 × 製造整合實踐」為主題，聚焦AI於生技製藥領域的多面向應用與成功實例，集結來自國內外專家，包含衛福部國家中醫藥研究所、達梭系統、MasterControl等領先單位， 共同剖析AI如何成為生技製藥產業的關鍵推進力、實踐潛力與未來機會。

本次論壇涵蓋三大亮點議題：
議題一、AI解碼生物訊號：從胜肽、外泌體到細胞的創新藥物開發方法
議題二、AI賦能藥品研發與實驗室自動化：加速藥品品質管理與生產製程革新
議題三、AI智慧製藥實踐轉型路徑：電子批次紀錄引領製藥製程與品質變革

謹代表訊聯集團誠摯邀請製藥廠、生技企業先進，CRDMO廠商與藥界學研機構共同參與。

 

Date / Time : July 25 14:00-17:00
Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 404)
Organizer : Department of Industrial Technology, MOEA
Co-organizer : Metal Industries Research & Development Centre, AG CORP, KENTRON

Time	Topic	Speaker
14:00-14:30	Admission
14:30-14:35	Opening Remarks & Group Photo	Representative from Department of Industrial Technology, MOEA
14:35-15:05	U.S. AI Healthcare Market and Innovation	Dov Shamir, PhD Founding Head of Elementa Labs Mount Sinai Health System
15:05-15:35	Challenges of U.S. Market Expansion: An International Entrepreneur’s Perspective	Vivian Feng CEO of AG CORP
15:35-16:05	The Role of Accelerators in the Scaling-Up Stage	John Lynn Co-Founder of QUAY
16:05-16:35	Navigating U.S. FDA Regulations and Government Grants (e.g., SBIR/STTR)	Kenny Wang CEO of HuaMei Business Center
16:35-17:00	Panel Discussion	Moderator: Vivian Feng, CEO of Accelerator Guardian Corp. Panelists: Dov Shamir, John Lynn, Kenny Wang, Pearl Chen

Session Synopsis:
This session explores essential strategies for healthcare innovators seeking to enter the competitive U.S. market. We'll examine regulatory pathways through the FDA, reimbursement considerations, partnership opportunities, and investment landscapes unique to the American healthcare ecosystem. Experts will share insights on navigating complex stakeholder relationships, addressing market-specific challenges, and positioning your innovation for successful commercialization. Whether you're developing medical devices, biotech solutions, digital health tools, or other healthcare innovations, you'll gain practical knowledge to develop a robust U.S. market entry strategy.
 

Date / Time : July 25 13:30–17:00

Venue : Taipei Nangang Exhibition Center, Hall 1 (Room 503)

Co-organizer : Purple Win Co., Ltd.

Time	Topic	Speaker
13:30–14:00	Registration
14:00–14:10	Opening Remarks	Session Chair
14:10–15:10	Advanced Morphological AI Analysis as a Process Analytical Technology for Quality by Design–Driven Process Development	Ryuji Kato Associate Professor, Nagoya University, Tokai National Higher Education and Research System
15:10–15:30	Coffee Break
15:30–15:40	2nd Opening Remark
15:40–16:40	Development of Robotic Automation System for Cell Manufacturing	Masahiro Kino-oka Professor, Department of Biotechnology, The University of Osaka
16:40–17:00	Closing Discussion